Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia

The introduction of imatinib (IM), a BCR-ABL1 tyrosine kinase inhibitor (TKI), has represented a significant advance in the first-line treatment of chronic myeloid leukemia (CML). However, approximately 30% of patients need to discontinue IM due to resistance or intolerance to this drug. Both resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Maia, Raquel C., Vasconcelos, Flavia C., Souza, Paloma S., Rumjanek, Vivian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017716/
https://www.ncbi.nlm.nih.gov/pubmed/29316665
http://dx.doi.org/10.3390/molecules23010119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017716/
https://www.ncbi.nlm.nih.gov/pubmed/29316665
http://dx.doi.org/10.3390/molecules23010119

Ejemplares similares